Discover how early functional screening at the single-cell level transforms therapeutic development of your antibodies.

A pioneering study uncovers crucial immune dynamics in hepatitis B, offering new insights into how immune responses evolve ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an ...

If liver failure occurs, it can lead to additional symptoms such as: Hepatitis B is an example of a condition that can cause acute and chronic liver inflammation. Acute symptoms may develop soon after ...

A silent infection is fuelling a rise in liver cancer deaths around the country, prompting the federal Health Department to consider universal hepatitis B testing for people aged over 25.

Objective: This study aimed to compare the prevalence of serum hepatitis B virus (HBV) markers in Inner Mongolia between 2006 and 2020. Methods: The same sampling process was used in investigations ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 health care workers in Catalonia who were followed for three years.

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the ...

complement-dependent cytotoxicity vs antibody-dependent cellular cytotoxicity), and Fc engineering. The discussion of these refinements includes improving the extent of B-cell depletion ...

For hepatitis B core antigen (HBcAg) staining, cells were fixed, permeabilised and blocked overnight at 4°C. Cells were stained with a combination of polyclonal rabbit HBc-antibody (DakoCytomation, ...

In addition to HBsAg, other viral markers such as hepatitis B core-related antigen (HBcrAg) are available, but their potential association with HBV-specific immune responses is not defined yet, which ...